



Emerging Challenges In Primary Care: *2012*

Activity Evaluation Summary

CME Activity: Emerging Challenges in Primary Care: 2012
Saturday, September 15, 2012
Sheraton Milwaukee Brookfield
Brookfield, WI

Course Director: Gregg Sherman, MD

**Date of Evaluation
Summary:** October 3, 2012



300 NW 70th Avenue, Suite 102 • Plantation, Florida 33317
(954) 723-0057 Phone • (954) 723-0353 Fax
email: info@naceonline.com

In September 2012, the National Association for Continuing Education (NACE) sponsored a CME program, ***Emerging Challenges in Primary Care: 2012***, in Milwaukee, WI.

This educational activity was designed to provide primary care physicians, nurse practitioners, physician assistants and other primary care providers the opportunity to learn about Diabetes, Atrial Fibrillation, Inflammatory Bowel Disease, Osteoporosis, Pulmonary Arterial Hypertension, Alpha-1 Antitrypsin Disorder, Idiopathic Pulmonary Fibrosis, and ADHD in Adults.

In planning this CME activity, the NACE performed a needs assessment. A literature search was conducted, national guidelines were reviewed, survey data was analyzed, and experts in each therapeutic area were consulted to determine gaps in practitioner knowledge, competence or performance.

One hundred thirteen healthcare practitioners registered to attend ***Emerging Challenges in Primary Care: 2012*** in Milwaukee, WI. Seventy eight healthcare practitioners actually attended this conference. Each attendee was asked to complete and return an activity evaluation form prior to the end of the conference. Seventy two completed forms were received. The data collected is displayed in this report.


CME ACCREDITATION

The National Association for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The National Association for Continuing Education designates this live activity for a maximum of 8 *AMA PRA Category 1 Credits*[™]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


What is your professional degree?

Label	Frequency	Percent	Valid Percent
MD	46	63.89	64.79
DO	4	5.56	5.63
NP	12	16.67	16.90
PA	9	12.50	12.68
RN	0	0.00	0.00
Other	0	0.00	0.00
Total Valid	71	98.61	100.00
Total Missing	1	1.39	
Total	72	100.00	




What is your specialty?

Label	Frequency	Percent	Valid Percent
Primary Care	57	79.17	79.17
Endocrinology	0	0.00	0.00
Rheumatology	1	1.39	1.39
Pulmonology	1	1.39	1.39
Cardiology	1	1.39	1.39
Gastroenterology	0	0.00	0.00
OB/GYN	2	2.78	2.78
Other	10	13.89	13.89
Total Valid	72	100.00	100.00




Upon completion of this activity, I can now - Address the importance of early diagnosis for enhancing outcomes in type 2 diabetes; identify evidence-based strategies for type 2 diabetes management; discuss the role of newer therapies in the pathophysiology and management of type 2 diabetes; and discuss the role of the chronic care model in optimizing diabetes care:

Label	Frequency	Percent	Valid Percent
Yes	63	87.50	87.50
Somewhat	9	12.50	12.50
Not at all	0	0.00	0.00
Total Valid	72	100.00	100.00




Upon completion of this activity, I can now - Describe the state-of-the-art approach to diagnosing idiopathic pulmonary fibrosis (IPF) from among a range of diffuse parenchymal lung disorders; Define prognostic features for individual IPF patients; Apply appropriate pharmacotherapeutic options for individual IPF patients while having a general understanding of the options under intense investigation; Discuss the role of available non-pharmacological therapies including pulmonary rehabilitation, oxygen supplementation and lung transplantation in IPF management:

Label	Frequency	Percent	Valid Percent
Yes	64	88.89	88.89
Somewhat	7	9.72	9.72
Not at all	1	1.39	1.39
Total Valid	72	100.00	100.00




Upon completion of this activity, I can now - Address the pathophysiology of PAH; discuss when and how to screen patients for PAH; identify current therapies in the management of PAH; and discuss how to appropriately monitor patients receiving treatment for PAH:

Label	Frequency	Percent	Valid Percent
Yes	59	81.94	81.94
Somewhat	9	12.50	12.50
Not at all	4	5.56	5.56
Total Valid	72	100.00	100.00




Upon completion of this activity, I can now - Describe the pathophysiology and impact of AAT deficiency; Define approaches for the early identification of patients with AAT deficiency; Discuss strategies to improve testing in primary care settings; Discuss management of patients with AAT:

Label	Frequency	Percent	Valid Percent
Yes	58	80.56	81.69
Somewhat	12	16.67	16.90
Not at all	1	1.39	1.41
Total Valid	71	98.61	100.00
Total Missing	1	1.39	
Total	72	100.00	




Upon completion of this activity, I can now - Describe existing guidelines and best practices in the diagnosis and treatment of ADHD in adults; identify risks for co-morbidities in adult patients with ADHD with emphasis on anxiety disorders, mood disorders, and substance use/abuse disorders; plan a pharmacologic treatment program for adults diagnosed with simple ADHD and more complex ADHD that is complicated by co-morbidities; identify psychosocial treatments for adults diagnosed with ADHD:

Label	Frequency	Percent	Valid Percent
Yes	52	72.22	81.25
Somewhat	12	16.67	18.75
Not at all	0	0.00	0.00
Total Valid	64	88.89	100.00
Total Missing	8	11.11	
Total	72	100.00	




Upon completion of this activity, I can now - Identify the conditions referred to as inflammatory bowel disease (IBD), and discuss their clinical presentations; implement appropriate pharmacologic and non-pharmacologic therapeutic strategies for managing IBD in accordance with evidence-based guidelines; tailor the available medications to the various presentations of IBD with attention to the induction and the maintenance of remission; use currently available laboratory tests to maximize benefit while minimizing toxicity; employ approaches for effectively communicating the risks and benefits of IBD treatment options and facilitating adherence:

Label	Frequency	Percent	Valid Percent
Yes	51	70.83	80.95
Somewhat	12	16.67	19.05
Not at all	0	0.00	0.00
Total Valid	63	87.50	100.00
Total Missing	9	12.50	
Total	72	100.00	




Upon completion of this activity, I can now - Use the CHADS2 score to assess stroke risk in patients with atrial fibrillation (AF); describe the benefits versus risks of antithrombotic therapy for stroke risk reduction in AF patients; identify appropriate therapeutic interventions for AF patients depending on the level of stroke risk; optimize the long-term management of AF patients receiving antithrombotic therapy:

Label	Frequency	Percent	Valid Percent
Yes	54	75.00	87.10
Somewhat	8	11.11	12.90
Not at all	0	0.00	0.00
Total Valid	62	86.11	100.00
Total Missing	10	13.89	
Total	72	100.00	




Upon completion of this activity, I can now - Discuss screening strategies for osteoporosis in postmenopausal women; identify candidates for pharmacologic treatment of postmenopausal osteoporosis; evaluate and compare available therapies for osteoporosis; and discuss barriers to adherence and effectiveness of osteoporosis therapy:

Label	Frequency	Percent	Valid Percent
Yes	50	69.44	89.29
Somewhat	6	8.33	10.71
Not at all	0	0.00	0.00
Total Valid	56	77.78	100.00
Total Missing	16	22.22	
Total	72	100.00	




Overall, I would rate this activity as:

Label	Frequency	Percent	Valid Percent
Excellent	44	61.11	63.77
Very Good	25	34.72	36.23
Good	0	0.00	0.00
Fair	0	0.00	0.00
Poor	0	0.00	0.00
Total Valid	69	95.83	100.00
Total Missing	3	4.17	
Total	72	100.00	




Overall, this activity was effective in enhancing my confidence in caring for patients with the condition(s) presented?

Label	Frequency	Percent	Valid Percent
Strongly Agree	39	54.17	56.52
Agree	30	41.67	43.48
Neutral	0	0.00	0.00
Disagree	0	0.00	0.00
Strongly Disagree	0	0.00	0.00
Total Valid	69	95.83	100.00
Total Missing	3	4.17	
Total	72	100.00	




Overall, this activity was effective in improving my knowledge in the content areas presented:

Label	Frequency	Percent	Valid Percent
Strongly Agree	46	63.89	66.67
Agree	23	31.94	33.33
Neutral	0	0.00	0.00
Disagree	0	0.00	0.00
Strongly Disagree	0	0.00	0.00
Total Valid	69	95.83	100.00
Total Missing	3	4.17	
Total	72	100.00	




As a result of this activity, I have learned new strategies for patient care:

Label	Frequency	Percent	Valid Percent
Strongly Agree	37	51.39	53.62
Agree	30	41.67	43.48
Neutral	2	2.78	2.90
Disagree	0	0.00	0.00
Strongly Disagree	0	0.00	0.00
Total Valid	69	95.83	100.00
Total Missing	3	4.17	
Total	72	100.00	




How likely are you to implement these new strategies in your practice?

Label	Frequency	Percent	Valid Percent
Very likely	42	58.33	66.67
Somewhat likely	14	19.44	22.22
Unlikely	1	1.39	1.59
Not applicable	6	8.33	9.52
Total Valid	63	87.50	100.00
Total Missing	9	12.50	
Total	72	100.00	




When do you intend to implement these new strategies into your practice?

Label	Frequency	Percent	Valid Percent
Within 1 month	43	59.72	68.25
1-3 months	8	11.11	12.70
4-6 months	5	6.94	7.94
Not applicable	7	9.72	11.11
Total Valid	63	87.50	100.00
Total Missing	9	12.50	
Total	72	100.00	




In terms of delivery of the presentation, please rate the effectiveness of the speaker: Robert Busch, MD (Diabetes):

Label	Frequency	Percent	Valid Percent
Excellent	37	51.39	52.86
Very Good	29	40.28	41.43
Good	4	5.56	5.71
Fair	0	0.00	0.00
Unsatisfactory	0	0.00	0.00
Total Valid	70	97.22	100.00
Total Missing	2	2.78	
Total	72	100.00	




In terms of delivery of the presentation, please rate the effectiveness of the speaker: Fernando Martinez, MD (IPF):

Label	Frequency	Percent	Valid Percent
Excellent	64	88.89	91.43
Very Good	6	8.33	8.57
Good	0	0.00	0.00
Fair	0	0.00	0.00
Unsatisfactory	0	0.00	0.00
Total Valid	70	97.22	100.00
Total Missing	2	2.78	
Total	72	100.00	




In terms of delivery of the presentation, please rate the effectiveness of the speaker: Franck Rahaghi, MD (PAH):

Label	Frequency	Percent	Valid Percent
Excellent	50	69.44	72.46
Very Good	18	25.00	26.09
Good	1	1.39	1.45
Fair	0	0.00	0.00
Unsatisfactory	0	0.00	0.00
Total Valid	69	95.83	100.00
Total Missing	3	4.17	
Total	72	100.00	




In terms of delivery of the presentation, please rate the effectiveness of the speaker: Franck Rahaghi, MD (AAT):

Label	Frequency	Percent	Valid Percent
Excellent	50	69.44	74.63
Very Good	15	20.83	22.39
Good	1	1.39	1.49
Fair	1	1.39	1.49
Unsatisfactory	0	0.00	0.00
Total Valid	67	93.06	100.00
Total Missing	5	6.94	
Total	72	100.00	




In terms of delivery of the presentation, please rate the effectiveness of the speaker: Anthony Rostain, MD (ADHD):

Label	Frequency	Percent	Valid Percent
Excellent	48	66.67	77.42
Very Good	13	18.06	20.97
Good	1	1.39	1.61
Fair	0	0.00	0.00
Unsatisfactory	0	0.00	0.00
Total Valid	62	86.11	100.00
Total Missing	10	13.89	
Total	72	100.00	




In terms of delivery of the presentation, please rate the effectiveness of the speaker: Gerald W. Dryden, MD (IBD):

Label	Frequency	Percent	Valid Percent
Excellent	35	48.61	58.33
Very Good	21	29.17	35.00
Good	4	5.56	6.67
Fair	0	0.00	0.00
Unsatisfactory	0	0.00	0.00
Total Valid	60	83.33	100.00
Total Missing	12	16.67	
Total	72	100.00	




In terms of delivery of the presentation, please rate the effectiveness of the speaker: Elizabeth Jackson, MD (A Fib):

Label	Frequency	Percent	Valid Percent
Excellent	42	58.33	75.00
Very Good	12	16.67	21.43
Good	2	2.78	3.57
Fair	0	0.00	0.00
Unsatisfactory	0	0.00	0.00
Total Valid	56	77.78	100.00
Total Missing	16	22.22	
Total	72	100.00	




In terms of delivery of the presentation, please rate the effectiveness of the speaker: Nelson Watts, MD (Osteo):

Label	Frequency	Percent	Valid Percent
Excellent	35	48.61	76.09
Very Good	11	15.28	23.91
Good	0	0.00	0.00
Fair	0	0.00	0.00
Unsatisfactory	0	0.00	0.00
Total Valid	46	63.89	100.00
Total Missing	26	36.11	
Total	72	100.00	




To what degree do you believe that the subject matter was presented fair, balanced, and free of commercial bias? Robert Busch, MD (Diabetes):

Label	Frequency	Percent	Valid Percent
Excellent	53	73.61	75.71
Very Good	17	23.61	24.29
Good	0	0.00	0.00
Fair	0	0.00	0.00
Unsatisfactory	0	0.00	0.00
Total Valid	70	97.22	100.00
Total Missing	2	2.78	
Total	72	100.00	




To what degree do you believe that the subject matter was presented fair, balanced, and free of commercial bias? Fernando Martinez, MD (IPF):

Label	Frequency	Percent	Valid Percent
Excellent	61	84.72	87.14
Very Good	9	12.50	12.86
Good	0	0.00	0.00
Fair	0	0.00	0.00
Unsatisfactory	0	0.00	0.00
Total Valid	70	97.22	100.00
Total Missing	2	2.78	
Total	72	100.00	




To what degree do you believe that the subject matter was presented fair, balanced, and free of commercial bias? Franck Rahaghi, MD (PAH):

Label	Frequency	Percent	Valid Percent
Excellent	60	83.33	85.71
Very Good	9	12.50	12.86
Good	1	1.39	1.43
Fair	0	0.00	0.00
Unsatisfactory	0	0.00	0.00
Total Valid	70	97.22	100.00
Total Missing	2	2.78	
Total	72	100.00	




To what degree do you believe that the subject matter was presented fair, balanced, and free of commercial bias? Franck Rahaghi, MD (AAT):

Label	Frequency	Percent	Valid Percent
Excellent	57	79.17	83.82
Very Good	10	13.89	14.71
Good	1	1.39	1.47
Fair	0	0.00	0.00
Unsatisfactory	0	0.00	0.00
Total Valid	68	94.44	100.00
Total Missing	4	5.56	
Total	72	100.00	




To what degree do you believe that the subject matter was presented fair, balanced, and free of commercial bias? Anthony Rostain, MD (ADHD):

Label	Frequency	Percent	Valid Percent
Excellent	54	75.00	88.52
Very Good	7	9.72	11.48
Good	0	0.00	0.00
Fair	0	0.00	0.00
Unsatisfactory	0	0.00	0.00
Total Valid	61	84.72	100.00
Total Missing	11	15.28	
Total	72	100.00	




To what degree do you believe that the subject matter was presented fair, balanced, and free of commercial bias? Gerald W. Dryden, MD (IBD):

Label	Frequency	Percent	Valid Percent
Excellent	52	72.22	86.67
Very Good	8	11.11	13.33
Good	0	0.00	0.00
Fair	0	0.00	0.00
Unsatisfactory	0	0.00	0.00
Total Valid	60	83.33	100.00
Total Missing	12	16.67	
Total	72	100.00	




To what degree do you believe that the subject matter was presented fair, balanced, and free of commercial bias? Elizabeth Jackson, MD (A Fib):

Label	Frequency	Percent	Valid Percent
Excellent	51	70.83	85.00
Very Good	8	11.11	13.33
Good	1	1.39	1.67
Fair	0	0.00	0.00
Unsatisfactory	0	0.00	0.00
Total Valid	60	83.33	100.00
Total Missing	12	16.67	
Total	72	100.00	




To what degree do you believe that the subject matter was presented fair, balanced, and free of commercial bias? Nelson Watts, MD (Osteo):

Label	Frequency	Percent	Valid Percent
Excellent	45	62.50	83.33
Very Good	8	11.11	14.81
Good	1	1.39	1.85
Fair	0	0.00	0.00
Unsatisfactory	0	0.00	0.00
Total Valid	54	75.00	100.00
Total Missing	18	25.00	
Total	72	100.00	




Which statement(s) best reflects your reasons for participating in this activity:

Label	Frequency	Percent	Valid Percent
Topics covered	55	76.39	78.57
Location/ease of access	59	81.94	84.29
Faculty	10	13.89	14.29
Earn CME credits	60	83.33	85.71
Total Valid	70	97.22	100.00
Total Missing	2	2.78	
Total	72	100.00	



Future CME activities concerning this subject matter are necessary:

Label	Frequency	Percent	Valid Percent
Strongly agree	27	37.50	39.71
Agree	35	48.61	51.47
Neutral	6	8.33	8.82
Disagree	0	0.00	0.00
Strongly Disagree	0	0.00	0.00
Total Valid	68	94.44	100.00
Total Missing	4	5.56	
Total	72	100.00	



What is your professional degree?

Comment
MPH

What is your specialty?

Comment
Occupational Medicine
Pain Management
Surgery
Pain Management
Dermatology
Radiology
Pain Management
Pain Management
Neurology
Orthopedics
Urgent Care

As a result of this activity, I have learned new strategies for patient care. List these strategies:

Comment
Monitoring patients and approach to patients with IBD, treatment of osteoporosis and use of FRAX
Better treatment, PH where see pt
Consider Prolia for Osteoporosis, refer more patients for ADD evaluation
Distinction between when to order CT vs. HRCT
Combination medications for IBD, and in some cases ADHD and DM, increased screening of patients for AAT deficiency, I will still treat CHAD2 score patients as dosing
Evaluation of IPF, treatments early referral for lung transplant, evaluation of echo for PH, value of Vg study, AAT testing, use of ASR scale in assessment of ADHD
Early diagnosis and treatment of Diabetes, increased screening for AATD, increased awareness and screening of adult ADHD
Will help with patient management and treatment
Screen for AAT deficiency on all COPD pts, treat DM aggressively with multi therapy sooner than later, IPF to dx use HRCT scan, PFT's, get on lung transplant list, Atrial Fib use CHADS score, anticoagulate
Stronger use of CHADS2 with AT9 update, use of polypharmacy in DM etc, despite polypharmacy being a dirty word, increase my search for AAT
Bone density test earlier for those with high risk, do CHADS2 evaluation on pt with Afib to evaluate for treatment, ask family member about pt coming in for ADHD sx
Screening tools for ADHD
Check for AAT deficiency in COPD, use scales for ADD
Improved diagnostic and treatment algorithms

Comment
More aggressive treatment of DM2, know how to work up pulmonary HTN and IPF, more confidence diagnosing ADHD in adults
Use CHADS more
I will actively use skills and knowledge in dx and Rx ADHD in adults, IPF, I will have to review more on DM Type II and IBD, tools provided for ADHD will be very useful
Use of ADHD self report scale
CHADS score
Early referral for IPF, early referral for PAH
CHADS score, adults report for ADD
Good understanding of IPF and ADHD in adults
Screen for ADHD, workup PAH, test for AAT, diagnose IPF
Good information as to how to diagnose and which patients, good information on how to ADHD
As a Radiologist I attend this course in an attempt to better communicate with my clinical colleagues and hopefully better serve them and their patients
CHADS2 score evaluation and document review toolkit for ADD in adults and use tools, in practice reconsider evaluation and Rx of Afib in my practice, use Fx score and Rx Osteoporosis absolutely be more aggressive in evaluation large dz especially in young pt, ATT deficiency
AAT and PAH when to refer, increased comfort levels
Tools to use for ADHD, FRAX
I will test for Alpha 1 def in my COPD patients, utilize DPP, Use stimulative vs non stimulative
Testing for AAT deficiency, anticoagulation for Afib
Learned screening, symptoms, what to order for confirmation, when to refer out, what NOT to do, more about medications
I learned many strategies for identify patients with these problems, referring them when needed, diagnosing and treating them. Several useful tools such as the ADHD tools and the online Frax tools will be very helpful. I will also continue to use the CHADS2 Score.
Assessment of risks, determination of diagnosis, better treatment
Team work, early diagnosis early treatment
Being more aggressive in treating DM earlier, testing for AAT, checking for PF, doing pt questionnaire for ADHD and IBD and looking into proper anticoagulation with Afib with newer agents other than Warfarin
Early detection and diagnosis, better understanding of disease which leads to better patient management, better monitoring of patients' responses
Early detection and diagnosis with appropriate tests or studies, initiate early and aggressive treatments, monitor, follow up regularly
Diagnosis and treatment
Use of high resolution CT to look for interstitial pulm dx, order testing of a lantitrypsin Ix on COPD patients, increase use of 6 min walk, consider evaluation of certain patients for ADHD, when to start ostopenia treatment with FRAX
Diagnosis of Type 2 DM, treatment and diagnosis of AAT deficiency
Better confidence with med choices for type 2 DM, using CHADS2 score to guide treatment of Afib, using FRAX to help determine when treatment needed for decreased bone density

What topics would you like to see offered as CME activities in the

future?

Comment
Approach to patient with renal failure, MS review
Obesity
Obesity, asthma, COPD, common endocrine
Same
No suggestions now
MRSA colonisation, bacteremia mgt
GI cancers, rheumatology topics
Obesity
Hypertension treatments, 10 topics, C. diff, MRSA
EKG interpretation, Anxiety and Depression in adolescents, sports injuries
Immunization, Hypertension, COPD
Infectious disease, Orthopedics, Dermatology
Hypertension, Thyroid Disorders and Asthma
Palliative care, Women's Health, Geriatrics, Polypham issues
PSA testing, Pap guidelines
Microscopit colitis
Hyperthyroidism
Dyslipidemia or Lipid disorders
HIV treatment options
Obesity, depression, chronic pain syndrome
HTN, CAD
Hypertension and Hepatitis C
Diabetes
Chest pain in primary care office
Obesity, fibromyalgia
Depression, Fibromyalgia, Chronic Pain, Mental health
Dermatology, OA
Obesity
Obesity
Re-imburement, neurology, nephrology, psychiatry, pain management
Dermatology, skin conditions
Pain management and complimentary medicine, integrative medicine
HTX, Lipids, connective tissue diseases
Atrial Fib and CHF, stroke
Type II Diabetes, Atrial Fibrillation, Osteoporosis, Rheumatoid Arthritis
Dermatology, Women's Health
Preventive Medicine
Women's Health, Endocrinology
Obesity
Celiac disease, cystic fibrosis
Cardiovascular, dermatology, women's health
Treatment options for autism, update on pap guidelines

Additional comments:

Comment
Great location, great handouts Thank you
Excellent conference. Thank you for providing this at no cost to participants. Please come back next year
Excellent, hope to see you next year
Great topics and speaker
Great topics Thank you
Very well done
Thank you
Really excellent conference with terrific speakers, hoping to attend next year
Excellent course thank you
Thanks for a great program, I do not mind to participate in the same topics next year
Excellent CME activity
Thank you Excellent speakers
Great day
Well done
Overall excellent experience
Well organized activity
Superb, excellent speakers, best conference I have attended in years
Very complete, a much appreciated good value
Information booklet for Diabetes it would be beneficial to include drug list of meds in each class
This conference was very, very good
Great conference
Excellent program, excellent speakers, very educational will attend this program in the future
Very interesting and helpful CME

Item Statistics:

	Title	Specialty	Learning Objectives1	Learning Objectives2	Learning Objectives3	Learning Objectives4	Learning Objectives5
Mean	1.77	2.26	1.13	1.13	1.24	1.20	1.19
Variance	1.29	6.70	0.11	0.14	0.30	0.19	0.15
Standard Deviation	1.14	2.59	0.33	0.37	0.54	0.43	0.39
Standard Error	0.13	0.31	0.04	0.04	0.06	0.05	0.05
Minimum	1.00	1.00	1.00	1.00	1.00	1.00	1.00
Maximum	4.00	8.00	2.00	3.00	3.00	3.00	2.00
Median	1.00	1.00	1.00	1.00	1.00	1.00	1.00
Range	3.00	7.00	1.00	2.00	2.00	2.00	1.00

	Learning Objectives6	Learning Objectives7	Learning Objectives8	Overall Activity	Enhancing My Confidence	Improving My Knowledge	Patient Care
Mean	1.19	1.13	1.11	1.36	1.43	1.33	1.49
Variance	0.16	0.11	0.10	0.23	0.25	0.23	0.31
Standard Deviation	0.40	0.34	0.31	0.48	0.50	0.47	0.56
Standard Error	0.05	0.04	0.04	0.06	0.06	0.06	0.07
Minimum	1.00	1.00	1.00	1.00	1.00	1.00	1.00
Maximum	2.00	2.00	2.00	2.00	2.00	2.00	3.00
Median	1.00	1.00	1.00	1.00	1.00	1.00	1.00
Range	1.00	1.00	1.00	1.00	1.00	1.00	2.00

	Make Changes	Implement New Strategies	Robert Busch MD {Diabetes}	Fernando Martinez MD {IPF}	Franck Rahaghi MD {PAH}	Franck Rahaghi MD {AAT}	Anthony Rostain MD {ADHD}
Mean	1.54	1.62	4.47	4.91	4.71	4.70	4.76
Variance	0.87	1.08	0.37	0.08	0.24	0.33	0.22
Standard Deviation	0.93	1.04	0.61	0.28	0.49	0.58	0.47
Standard Error	0.12	0.13	0.07	0.03	0.06	0.07	0.06
Minimum	1.00	1.00	3.00	4.00	3.00	2.00	3.00
Maximum	4.00	4.00	5.00	5.00	5.00	5.00	5.00
Median	1.00	1.00	5.00	5.00	5.00	5.00	5.00
Range	3.00	3.00	2.00	1.00	2.00	3.00	2.00

	Gerald W Dryden MD {IBD}	Elizabeth Jackson MD {A Fib}	Nelson Watts MD {Osteo}	Robert Busch MD {Diabetes} Bias	Fernando Martinez MD {IPF} Bias	Franck Rahaghi MD {PAH} Bias	Franck Rahaghi MD {AAT} Bias
Mean	4.52	4.71	4.76	4.76	4.87	4.84	4.82
Variance	0.39	0.28	0.19	0.19	0.11	0.16	0.18
Standard Deviation	0.62	0.53	0.43	0.43	0.34	0.40	0.42
Standard Error	0.08	0.07	0.06	0.05	0.04	0.05	0.05
Minimum	3.00	3.00	4.00	4.00	4.00	3.00	3.00
Maximum	5.00	5.00	5.00	5.00	5.00	5.00	5.00
Median	5.00	5.00	5.00	5.00	5.00	5.00	5.00
Range	2.00	2.00	1.00	1.00	1.00	2.00	2.00

	Anthony Rostain MD {ADHD} Bias	Gerald W Dryden MD {IBD} Bias	Elizabeth Jackson MD {A Fib} Bias	Nelson Watts MD {Osteo} Bias	Reasons for Participating	Future CME Activities
Mean	4.89	4.87	4.83	4.81	-	1.69
Variance	0.10	0.12	0.18	0.19	-	0.40
Standard Deviation	0.32	0.34	0.42	0.44	-	0.63
Standard Error	0.04	0.04	0.05	0.06	-	0.08
Minimum	4.00	4.00	3.00	3.00	-	1.00
Maximum	5.00	5.00	5.00	5.00	-	3.00
Median	5.00	5.00	5.00	5.00	-	2.00
Range	1.00	1.00	2.00	2.00	-	2.00